Snider MA, et al. - In this randomized, nonblinded, noninferiority study conducted at a single pediatric tertiary care Emergency Department, a comparison of the clinical efficacy of breath-actuated nebulizer (BAN) and the metered-dose inhaler (MDI) was performed in treating subjects (patients 2 to 17 years of age) presenting with mild to moderate asthma exacerbations. They administered albuterol by BAN or MDI via standard weight-based and symptom severity dosing protocols to the subjects presenting with a Pediatric Asthma Score ranging from 5 to 11. When clinically indicated, aerosolized ipratropium (via BAN) and intravenous magnesium sulfate were given. As per outcomes, albuterol therapy by MDI was demonstrated to be noninferior to BAN for the treatment of mild to moderate asthma exacerbations in children 2 to 17 years of age.